Publications

5599 Results

CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma

Authors
G Abou-Alfa;S Geyer;A Nixon;F Innocenti;Q Shi;S Jacobson;I El Dika;A Yaqubie;J Lopez;B Hwang;A El-Khoueiry;Y Tang;Y Wen;L Schwartz;M Bertagnolli;J Meyerhardt;E O'Reilly;A Venook
Journal / Conference
Cancer Research Communications Mar 7;4(3):682-690
Year
2024
Research Committee(s)
Gastrointestinal
PMID
PMID38363156
PMC
PMC10919207
Study Number(s)
CTSU/C80802

Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children

Authors
A Lo;A Liu;Q Liu;Y Yasui;S Catellino;K Kelly;A Hererra;JW Friedberg;D Friedman;C Schwartz;Q Pei;S Kessel;S Bergeron-Gravel;H Dama;K Roberts;L Constine;D Hodgson
Journal / Conference
JAMA Network Open Jan 2;7(1):e2351062
Year
2024
Research Committee(s)
Lymphoma
PMID
PMID38241048
PMC
PMC10799264
Study Number(s)
S1826

Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer

Authors
H Arai;Y Yang;J Millstein;T Denda;F Ou;F Innocenti;H Takeda;Y Kubota;A Doi;Y Horie;K Umemoto;N Izawa;J Wang;F Battaglin;P Jayachandran;S Algaze;S Soni;W Zhang;W Zhang;R Goldberg;M Hall;A Scott;J Hwang;E Lou;B Weinberg;J Marshall;S Goel;J Xiu;M Korn;A Venook;Y Sunakawa;H-J Lenz
Journal / Conference
European Journal of Cancer Apr:201:113914
Year
2024
Research Committee(s)
Gastrointestinal
PMID
PMID: 38359495
Study Number(s)
CTSU/C80405

Long Term Follow-up from A041202, A Phase 3 Study of Bendamustine/Rituximab vs Ibrutinib or Ibrutinib/Rituximab Shows Continued Efficacy and Safety of Ibrutinib in Older Adults with CLL

Authors
J Woyach;G Burbano;A Ruppert;C Miller;N Heerema;W Zhao;A Wall;W Ding;N Bartlett;D Brander;P Barr;K Rogers;S Parekh;D Stephens;J Brown;G Lozanski;J Blachly;S Nattam;R Larson;H Erba;M Litzow;S Lugar;C Owen;C Kuzma;J Abramson;R Little;S Dinner;R Stone;G Uy;W Stock;S Mandrekar;J Byrd
Journal / Conference
Blood Jan 12:blood.2023021959. doi: 10.1182/blood.2023021959. Online ahead of print
Year
2024
Research Committee(s)
Leukemia
PMID
PMID38215395
PMC
PMC1110309
Study Number(s)
CTSU/A041202

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 48) in Patients with Advanced Gallbladder Cancer

Authors
S Patel;E Guadarrama;Y Chae;M Dennis;B Powers;C-Y Liao;W Ferri;T George;E Sharon;C Ryan;M Othus;G Lopez;C Blanke;R Kurzrock
Journal / Conference
Cancer Sep 1;130(17):2918-2927
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID38358334
PMC
PMC11309904
Study Number(s)
S1609

Diversity of Patients Enrolled in SWOG Gastrointestinal Cancers Therapeutic Trials

Authors
R Safyan;S Colby;C Figueroa-Moseley;K Guthrie;EG Chiorean;PA Philip
Journal / Conference
J Clin Oncol 42, 2024 (suppl 3; abstr 726); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA, poster
Year
2024
Research Committee(s)
Gastrointestinal

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): a subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel [Brief Report]

Authors
P Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M Van Loan;M Hussain;S Gupta;J Zhang;M Parikh;P Twardowski;D Quinn;M LeBlanc;I Thompson;N Agarwal
Journal / Conference
Prostate Cancer and Prostatic Diseases Feb 29. doi: 10.1038/s41391-024-00813-3. Online ahead of print
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID38424319
Study Number(s)
S1216

Three- and seven- month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel or bicalutamide

Authors
M Parikh;C Tangen;M Hussain;S Gupta;Y Jo;S Callis;A Harzstark;C Paller;S George;M Zibelman;H Cheng;B Maughan;J Zhang;R Pachynski;A Bryce;D Lin;D Quinn;I Thompson;SP Lerner;T Dorff;P Lara;N Agarwal
Journal / Conference
European Urology Oncology Oct;7(5):1097-1104
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID38523017
Study Number(s)
S1216

SWOG S1820: A Pilot Randomized Trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer (AIMS-RC)

Authors
V Sun;KA Guthrie;T Crane;K Arnold;S Colby;S Freylersythe;C Braun-Inglis;R Topacio;C Messick;J Carmichael;A Muskovitz;M Nashawaty;M Bajaj;S Cohen;D Flaherty;M O'Rourke;L Jones;R Krouse;C Thomson
Journal / Conference
Cancer Feb 22. doi: 10.1002/cncr.35264. Online ahead of print
Year
2024
Research Committee(s)
Palliative Care
PMID
PMID38386696
PMC
PMC11162313
Study Number(s)
S1820

Analysis of immune-related genes (IRGs) and their potential role in sexual dimorphism in metastatic colorectal cancer (mCRC) patients (pts)

Authors
P Mittal;Y Yang;S Soni;F Battaglin;J Millstein;S Stintzing;A Parikh;J Lo;L Torres-Gonzalez;S Algaze;P Jayachandran;K Ashouri;A Wong;W Zhang;C Mancao;C Cremolini;V Heinemann;I Singh;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 3; abstr 182)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405